Hyaluronic acid/triamcinolone acetonide - Carbylan Therapeutics

Drug Profile

Hyaluronic acid/triamcinolone acetonide - Carbylan Therapeutics

Alternative Names: Hydros-TA

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Carbylan BioSurgery
  • Developer KalVista Pharmaceuticals
  • Class Analgesics; Corticosteroids; Fluorinated steroids; Glycosaminoglycans; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Pain

Most Recent Events

  • 22 Nov 2016 Carbylan Therapeutics has been acquired and merged into KalVista Pharmaceuticals
  • 01 Jun 2016 Carbylan completes a phase III clinical trial for Pain in Netherlands Antilles, Australia, Canada, Europe, New Zealand (Intra-articular) (9190751; NCT02022930)
  • 22 Apr 2016 Suspended - Phase-II for Pain in West Indies (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top